Abstract
Background
During the first and second COVID-19 pandemic waves, children, despite susceptible to SARS-CoV-2 infection, appeared at lower risk of severe disease, hospitalization, and death than adults and the elderly. Moreover, they seemed to play a minor role in the diffusion of the virus. The aim of this manuscript is to show epidemiological surveillance on COVID-19 incidence and hospitalization in the pediatric cohort in order to explain the importance of an adequate COVID-19 vaccination coverage in the pediatric population.
Methods
All subjects with documented SARS-CoV-2 infection diagnosed in Parma, Italy, between February 21st, 2020, and January, 31st, 2022, were recruited in this epidemiological surveillance. Diagnosis of infection was established in presence of at least one respiratory specimen positive for SARS-CoV-2 nucleic acid using a validated real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay.
Results
The number of COVID-19 pediatric cases remained very low and lower than that recorded in the general population between early February 2020 and the end of October 2021, despite in the last part of this period the Delta variant emerged. On the contrary, starting from November 2021, a sharp and significant increase in COVID-19 incidence in the pediatric population was evidenced. This was detected in all the age groups, although greater in the populations aged 5–11 and 12–17 years old. Interestingly, the peak in hospitalization rate was observed in children < 5 years old, for whom COVID-19 vaccination is not approved yet. At the beginning of November 2021 among people older than 18 years of age 85.7% had completed the primary series of COVID-19 vaccine. Almost all the infants and pre-school children were susceptible. Until January 31st, 2022, 80.4% of adolescents aged 11–17 years had received at least two doses of COVID-19 vaccine and only 52.4% received the booster. Among children 5–11 years old, on January 31st, 2022, only 28.5% had received at least one vaccine dose.
Conclusions
Compared with adults and the elderly, presently a greater proportion of children and adolescents is susceptible to SARS-CoV-2 and could play a relevant role for the prolongation of the COVID-19 pandemic. Only a rapid increase in vaccination coverage of the pediatric populations can effectively counter this problem.
Keywords: COVID-19, COVID-19 vaccines, Epidemiology, Pediatric infectious diseases, SARS-CoV-2
Introduction
During the first and second COVID-19 pandemic waves, children, despite susceptible to SARS-CoV-2 infection, appeared at lower risk of severe disease, hospitalization, and death than adults and the elderly [1–3]. Moreover, although they could transmit the infection, they seemed to play a minor role in the diffusion of the virus [4]. Along with the negative physical and mental impact, this was one of the most important reasons why many experts opposed the school closure as a measure to contain virus circulation [5–7]. With the extension of the pandemic, the emergence of viral variants and the development and use of effective and safe vaccines, the role of the pediatric population in the spread of SARS-CoV-2 has changed substantially. The aim of this manuscript is to show epidemiological surveillance on COVID-19 incidence and hospitalization in the pediatric cohort in order to explain the importance of an adequate COVID-19 vaccination coverage in the pediatric population.
Methods
The province of Parma, a city with 194,417 inhabitants of whom 71,558 < 18 years of age, is located in Northern Italy and its health facilities were particularly involved in the first pandemic wave [8]. All subjects with documented SARS-CoV-2 infection diagnosed in Parma between February 21st, 2020, and January, 31st, 2022, were recruited in this epidemiological surveillance. Diagnosis of infection was established in presence of at least one respiratory specimen positive for SARS-CoV-2 nucleic acid using a validated real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay. Results of the specimens and on patients’ outcome were provided by the Department of Public Health of AUSL Parma, that collects all the results of subjects tested for SARS-CoV-2 using RT-PCR in the city.
Results
Figure 1 shows epidemiological surveillance on COVID-19 incidence and hospitalization in the pediatric cohort. The number of COVID-19 pediatric cases remained very low and lower than that recorded in the general population between early February 2020 (i.e., the onset of the pandemic) and the end of October 2021, despite in the last part of this period the Delta variant emerged. On the contrary, starting from November 2021, a sharp and significant increase in COVID-19 incidence in the pediatric population was evidenced. This was detected in all the age groups, although greater in the populations aged 5–11 and 12–17 years old. Interestingly, the peak in hospitalization rate was observed in children < 5 years old, for whom COVID-19 vaccination is not approved yet. Main reasons for hospitalization included diarrhea/vomiting (39%), respiratory distress/pneumonia (31%) and febrile seizures (11%).
Fig. 1.
Surveillance on COVID-19 incidence (A) and hospitalization (B) in a pediatric cohort of 71,558 inhabitans
Discussion
Omicron SARS-CoV-2 variant has increased transmissibility than the original SARS-CoV-2 [9] and it cannot be excluded that, despite children were less susceptible than adults to the original virus [10], they can be more easily infected by the new virus. Moreover, when Omicron appeared, a great number of adults and elderlies had a certain degree of protection against this virus as many of them had been already infected or vaccinated against SARS-CoV2. At the beginning of November 2021 among people older than 18 years of age living in Parma 85.7% had completed the primary series of COVID-19 vaccine. On the contrary, children and adolescents with adequate protection were quite few. Almost all the infants and pre-school children were susceptible as very few had been previously infected and none of them was vaccinated. Vaccination of adolescents aged 11–17 years was introduced in May 2021: until January 31st, 2022, 80.4% of them had received at least two doses of COVID-19 vaccine and only 52.4% received the booster. Among children 5–11 years old, for whom vaccine was authorized in December 2021, on January 31st, 2022, only 28.5% had received at least one vaccine dose and coverage remained less than 35% up to March 30th, 2022.
Conclusions
Compared with adults and the elderly, presently a greater proportion of children and adolescents is susceptible to SARS-CoV-2. Since, based on the global epidemiological data, health authorities currently tend to avoid further restrictive measures, it seems likely that children could play a relevant role for the prolongation of the COVID-19 pandemic. Only a rapid increase in vaccination coverage of the pediatric populations can effectively counter this problem. Every effort must be made to persuade parents who are uncertain or against COVID-19 vaccines. Moreover, an effective and safe vaccine for children < 5 years old must be quickly approved for emergency use.
Acknowledgements
Not applicable.
Abbreviation
- RT-PCR
Real-time reverse-transcriptase polymerase-chain-reaction
Authors’ contributions
SE designed the project and wrote the first draft of the manuscript. RG, GP and CC had in charge the epidemilogical surveillance. NP co-wrote the manuscript. MP and CC analysed the data and gave a substantial scientific contributions. All authors approved the final version of the manuscript.
Funding
None.
Availability of data and materials
All data generated during this study are included in the published article.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interest.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Sinha IP, Harwood R, Semple MG, Hawcutt DB, Thursfield R, Narayan O, et al. COVID-19 infection in children. Lancet Respir Med. 2020;8:446–447. doi: 10.1016/S2213-2600(20)30152-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Esposito S, Caramelli F, Principi N. What are the risk factors for admission to the pediatric inten-sive unit among pediatric patients with COVID-19? Ital J Pediatr. 2021;47:103. doi: 10.1186/s13052-021-01057-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Esposito S, Marchetti F, Lanari M, Caramelli F, De Fanti A, Vergine G, et al. COVID-19 management in the pediatric age: consensus document of the COVID-19 working group in paediatrics of the Emilia-Romagna region (RE-CO-Ped), Italy. Int J Environ Res Public Health. 2021;18:3919. doi: 10.3390/ijerph18083919. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Li X. The role of children in transmission of SARS-CoV-2: a rapid review. J Glob Health. 2020;10:011101. doi: 10.7189/jogh.10.011101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Esposito S, Zona S, Vergine G, Fantini M, Marchetti F, Stella M, et al. How to manage children if a second wave of COVID-19 occurs. Int J Tuberc Lung Dis. 2020;24:1116–1118. doi: 10.5588/ijtld.20.0543. [DOI] [PubMed] [Google Scholar]
- 6.Esposito S, Principi N. School closure during the coronavirus disease 2019 (COVID-19) pandemic: an effective intervention at the global level? JAMA Pediatr. 2020;174:921–922. doi: 10.1001/jamapediatrics.2020.1892. [DOI] [PubMed] [Google Scholar]
- 7.Esposito S. Pediatricians of Emilia-Romagna region, Italy. Manifesto of the pediatricians of Emilia-Romagna region, Italy, in favor of vaccination against COVID in children 5-11 years old. Ital. J Pediatr. 2022;48:40. doi: 10.1186/s13052-022-01229-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Caminiti C, Maglietta G, Meschi T, Ticinesi A, Silva M, Sverzellati N. Effects of the COVID-19 epidemic on hospital admissions for non-communicable diseases in a large Italian University-hospital: a descriptive case-series study. J Clin Med. 2021;10:880. doi: 10.3390/jcm10040880. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, et al. Transmission dynamics and mutational prevalence of the novel SARS-CoV-2 omicron variant of concern. J Med Virol. 2022. 10.1002/jmv.27611. [DOI] [PMC free article] [PubMed]
- 10.Cusenza F, Davino G, D'Alvano T, Argentiero A, Fainardi V, Pisi G, et al. Silence of the lambs: the immunological and molecular mechanisms of COVID-19 in children in comparison with adults. Microorganisms. 2021;9:330. doi: 10.3390/microorganisms9020330. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated during this study are included in the published article.